CIK 0001680581
- Non-accelerated filer
- Smaller reporting company
Fulcrum Therapeutics, Inc.
Sign in to watch- Ticker
- FULC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 474839948
- Phone
- +1 617-651-8851
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- 4 Open-market sale SVP Clinical Development sold 401 shares at $22.00 ($8,822)
- 4 Open-market sale See Remarks sold 156 shares at $20.00 ($3,120)
- 4 Open-market sale See Remarks sold 3,433 shares at $20.17 ($69,251)
- 4 Open-market sale SVP Clinical Development sold 677 shares at an average $20.14 ($13,632)
- 4 Open-market sale See Remarks sold 2,800 shares at an average $20.09 ($56,250)
- 4 Open-market sale SVP Clinical Development sold 383 shares at an average $20.16 ($7,720)
- 4 Open-market sale See Remarks sold 2,802 shares at $20.00 ($56,040)
- 4 Open-market sale SVP Clinical Development sold 800 shares at an average $20.01 ($16,007)
- 4 Open-market sale See Remarks sold 3,309 shares at an average $20.04 ($66,302)
- 4 Open-market sale Chief Scientific Officer sold 2,232 shares at $20.00 ($44,640)
- 4 Open-market sale Chief Scientific Officer sold 448 shares at $20.00 ($8,960)
- 4 Open-market sale Chief Scientific Officer sold 412 shares at $20.00 ($8,240)
- 4 Open-market sale See Remarks sold 2,500 shares at $20.00 ($50,000)
- 4 Open-market sale SVP Clinical Development sold 1,860 shares at $18.00 ($33,480)
- 4 Open-market sale VP Finance & Accounting sold 7,500 shares at $16.00 ($120,000)
- 4 Open-market sale SVP Clinical Development sold 2,143 shares at an average $17.38 ($37,255)
- 4 Open-market sale VP Finance & Accounting sold 5,000 shares at an average $16.83 ($84,153)
- 4 Open-market sale See Remarks sold 2,500 shares at $20.00 ($50,000)
- 4 Open-market sale Chief Scientific Officer sold 6,088 shares at $20.00 ($121,760)
- 4 Open-market sale SVP Clinical Development sold 2,143 shares at $17.33 ($37,142)
Page 9 of 12 · 221 filings